Published in final edited form as:

Prog Pediatr Cardiol. 2014 December 1; 37(1-2): 23–27. doi:10.1016/j.ppedcard.2014.10.006.

Patient-Specific Pluripotent Stem Cells in Doxorubicin Cardiotoxicity: A New Window Into Personalized Medicine

Daniel Bernstein, M.D. and Paul Burrridge, Ph.D.

Departments of Pediatrics and Medicine, Stanford Cardiovascular Institute, Stanford University

Introduction

The anthracycline doxorubicin is one of the oldest, yet most effective, anti-cancer agents known. Doxorubicin is used in treating a wide range of malignancies and is currently utilized in 50–60% of breast cancer and 70% of childhood cancer treatment protocols. In children, anthracyclines have contributed to the dramatically increased 5-year survival rates for childhood cancer, now greater than 80% (1). Almost immediately after the use of doxorubicin began, the presence of dose-dependent cardiotoxicity was recognized (2,3). A review of three anthracycline trials (4) found the incidence of significant left ventricular dysfunction (reduction in ejection fraction [EF] of >10% below normal) was 16.2%, 32.4%, and 65.4% at cumulative doxorubicin doses of 300, 400, and 550 mg/m², respectively. Even at relatively low doses (cumulative doses of 200–250 mg/m²), the risk of cardiotoxicity was found to be as high as 8–9%.

However, with improved methods of detecting subtle changes in cardiac function (5), the incidence of doxorubicin cardiotoxicity is now thought to be much higher, occurring in up to 65% of long-term survivors of childhood cancer, even at doses as low as 228 mg/m² (6–8). Using echo indices such as wall stress rather than symptoms, 90% of children manifest subtle abnormalities in cardiac function during their first year of doxorubicin therapy (9). These data also suggest that patients develop subclinical cardiotoxicity rather than true “latency” between drug exposure and onset of symptoms (6). As many as 16% of children with these abnormalities will develop subsequent clinical heart failure (2,3,10) with a mortality rate as high as 72% (1,2,10). The incidence of heart failure in adults receiving anthracyclines appears to be lower than in children, although similar high-sensitivity echo studies (e.g. wall stress) have not been performed in adults. This greater risk for cardiotoxicity in children suggests that the immature heart may be more susceptible to anthracycline damage (5) which may correlate with studies showing increased susceptibility of cardiac progenitor cells to anthracyclines (11,12). With 1 in 750 adults now being

© 2014 Elsevier Ireland Ltd. All rights reserved.

Contact Information: Daniel Bernstein, M.D., 750 Welch Road Suite 325, Palo Alto, CA 94304, Phone 650-723-7913, Fax 650-725-8343, danb@stanford.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

survivors of childhood cancer, this problem represents a major challenge in the newly emerging field of cardio-oncology.

Mechanisms of doxorubicin-induced cardiotoxicity

Despite more than 50 years of research, the mechanism of doxorubicin cardiotoxicity is still incompletely understood, but can be grouped into three interrelated subgroups: (i) generation of reactive oxygen species (ROS), both dependent and independent of iron; (ii) mitochondrial dysregulation; and (iii) topoisomerase II inhibition causing double stranded break-induced apoptosis and transcriptional modulation of the mitochondrial and nuclear genomes. Several studies have implicated oxidative stress, as evidenced by ROS formation, as a central mechanism of doxorubicin cardiotoxicity (13,14). Doxorubicin can undergo a one- or two-electron reduction by several oxidoreductases to doxorubicin-semiquinone or doxorubicinol (15). In the presence of iron, re-oxidation of the doxorubicin-semiquinone or doxorubicinol radical back to doxorubicin leads to the formation of O_2^- and H_2O_2 . These ROS can establish redox cycling, producing more free radicals. Doxorubicin can also induce Ca^{2+} release from the sarcoplasmic reticulum (16) leading to sarcomeric disarray, myofibril deterioration and, as we have shown, increased likelihood of opening of the mitochondrial permeability transition (MPT) pore (17).

Cardiomyocytes may be uniquely at risk of doxorubicin toxicity due to their high number of mitochondria, representing 30% of cardiomyocyte volume (18). The majority of ROS producing enzymes such as NAD(P)H oxidase are located in the mitochondria and in the closely adjacent sarcoplasmic reticulum, so that the major sites of ROS production are located there. Doxorubicin also nearly irreversibly binds to cardiolipin on the mitochondrial membrane, maintaining localization (19) and also disrupting electron transport chain function. This localized production of ROS induces mitochondrial DNA (mtDNA) depletion (20) and mitochondrial membrane lipid peroxidation, leading to reduced mitochondrial function, reduced ATP production and ultimately apoptosis. Doxorubicin can also induce apoptotic pathways independent of ROS through the caspase-3 pathway (21).

Finally, doxorubicin binds DNA and topoisomerase II to form the ternary doxorubicin-DNA cleavage complex, which triggers cell death. Doxorubicin's effect on topoisomerase was initially felt to be responsible only for its anti-cancer effects (mediated through TOP2 α), not its cardiotoxic effects (since myocytes only express TOP2 β). However, a recent report shows that doxorubicin cardiotoxicity can be attenuated by cardiac-specific deletion of TOP2 β , potentially mediated via altered transcription of PGC-1 α and PGC-1 β (22).

Single nucleotide polymorphism (SNP) association studies of doxorubicin cardiotoxicity

At present, it is not possible to predict clinically which patients will be affected by doxorubicin cardiotoxicity (23), so that standard practice has been to limit the cumulative dose of doxorubicin for all patients, thereby reducing its anti-tumor efficacy. In an attempt to discover if there is a genetic basis for the predilection to doxorubicin cardiotoxicity, several gene variant association studies have been performed. One of the largest to date is a

multi-center doxorubicin cardiotoxicity analysis involving children enrolled at 11 sites participating in The Canadian Pharmacogenomics Network for Drug Safety. A discovery cohort of 344 Canadian patients (78 cases and 266 controls), was genotyped for 2,977 drug biotransformation (absorption, distribution, metabolism and elimination or ADME) genetic variants (24). An in-depth clinical characterization of patients was followed by grading of cardiac dysfunction as measured by echocardiogram and/or symptoms requiring intervention. A stringent fractional shortening (FS) threshold of 26% or less after anthracycline therapy was used to define cardiotoxicity, rather than alterations in wall stress. Control patients were defined as those having normal echocardiograms (FS of 30% or greater) for at least 5 years after completion of therapy.

Using this targeted approach, three significantly associated genetic variants were identified in two different genes: the nucleoside/anti-cancer drug transporter *SLC28A3* (rs7853758 and rs885004, which are in high linkage disequilibrium [LD]) and UDP glucuronosyltransferase 1A6 *UGT1A6* (rs17863783). The *SLC28A3* variants, one of which is a synonymous coding variant (L461L), are highly protective against the development of anthracycline-induced cardiotoxicity. In contrast, the highly associated variant in *UGT1A6* (a tag SNP for the reduced enzyme activity *UGT1A6**4 haplotype) significantly enhanced patient susceptibility to anthracycline-induced cardiotoxicity. These associations were then replicated in two additional patient cohorts (24,25). In the combined cohorts, the associations with *SLC28A3* (rs7853758) and *UGT1A6* (rs17863783) have extremely high odds ratios of 0.36 and 4.30 and extremely low *P*-values of 1.6×10^{-5} and 2.4×10^{-4} , respectively.

SLC28A3, a sodium-coupled nucleoside transporter is broadly selective for both pyrimidines and purines, plays a key role in the cellular uptake of a variety of anti-cancer drugs, and has been implicated in doxorubicin intracellular transport (26). *SLC28A3* is widely expressed in the body, including in cardiac tissue (27). Although the rs7853758 variant is synonymous at the amino acid level (L461L), it is associated with a 46% decrease in mRNA expression in carriers of the variant ($P = 4.68 \times 10^{-10}$) (28,29). Several studies provide supportive evidence for the functional importance of rs7853758 or a linked variant in chemotherapy response (30). There are also several loci in high linkage disequilibrium ($r^2 > 0.8$) with rs7853758, several of which may provide putative mechanisms for influencing doxorubicin cardiotoxicity: rs885004 which resides in a DNase hypersensitive and open chromatin region, with evidence of binding the insulator CTCF and disrupting transcription factor binding sites for NKX6-2; and rs4877835, which is in an open and active chromatin region with evidence of binding the activator protein 1 (AP-1) complex (c-JUN and c-FOS) and is predicted to disrupt binding by the myogenic transcription factor, MYF. Together, these functional annotations of the haplotype at *SLC28A3* suggest that variants in high LD with the variant rs7853758 could explain *cis*-regulatory mechanisms of doxorubicin cardiotoxicity through altered *SLC28A3* gene expression.

To uncover novel genetic associations with anthracycline cardiotoxicity, a GWAS study is in progress, and preliminary results show 25 significant SNPs, of which, only two were located in gene coding regions (*RARG*, encoding the γ retinoic acid receptor and *WDR4*, encoding a WD repeat domain). Further exploration of these two SNPs is currently in progress. Retinoic acid receptors (RARs) act as ligand-dependent transcriptional regulators

which activate transcription by binding to retinoic acid response elements (RARE) found in the promoter regions of their target genes. In their unbound form, RARs repress transcription of these target genes. RAR γ plays an important role in early cardiac development (31), in stem cell transcriptional regulation (32) and, importantly, in regulation of topoisomerase 2 β (33), a recently described regulator of doxorubicin cardiotoxicity (22).

Other doxorubicin cardiotoxicity studies concentrating on smaller numbers of SNPs and, in some, fewer patients (with reduced statistical power) have been completed. Of the larger studies, Blanco *et al.* performed a 487 patient/two variant study on children with doxorubicin cardiotoxicity and identified a carbonyl reductase 3 (*CBR3*) SNP as a predictor of cardiotoxicity (34). Carbonyl reductases are involved in the formation of the alcohol metabolite of doxorubicin, doxorubicinol. The *in vitro* studies of this variant are conflicting, with some showing decreased activity of the variant protein with doxorubicin (35,36) and others showing increased activity using menadione (37). A second study of SNPs of 82 genes from 1697 patients, 3.2% of whom developed either acute or chronic doxorubicin cardiotoxicity, found five significant associations in the NAD(P)H oxidase complex (*CYBA*, *NCF4*, and *RAC2*) (38). Consistent with this finding, mice deficient in NAD(P)H oxidase were resistant to doxorubicin cardiotoxicity (38). An additional 108 patient study showed a similar association (39). Smaller screens have identified SNPs in *ABCB1* (40), *ABCC2* (41), *NADPH oxidase* (42), catalase (*CAT*) (43), and the hemochromatosis gene *HFE* (41,44) associated with doxorubicin cardiotoxicity.

Although these studies represent a potential major advance in applying a pharmacogenomic approach to the field of cardio-oncology, the true connection between these SNPs and cardiotoxicity is far from proven. Given the difficulty that has been experienced in the past in transitioning GWAS data into clinical practice, it is vital that each of these candidate SNPs be confirmed in large replicate patient cohorts, and then validated using a suitable model system.

Human induced pluripotent stem cell-derived cardiomyocytes as models of cardiovascular disease

hiPSC-CMs (human induced pluripotent stem cell-derived cardiomyocytes) represent an important new model system for studying cardiovascular disease, especially given the major limitations in culturing human cardiomyocytes (45). hiPSCs are cells derived from adult somatic cells (e.g. skin, fat or white blood cells) obtained from patients that have been reprogrammed through genetic modification to behave like embryonic stem cells. These cells are pluripotent, which means that they have the ability to form all adult cell types. Dr. Shinya Yamanaka created the first iPSCs from a mouse in 2006 and from a human in 2007 and, together with Sir John Gurdon, received the Nobel Prize for this pioneering work in 2012. hiPSCs can then be differentiated into many different cell types, including contracting cardiomyocytes (hiPSC-CMs). Chemically defined, growth factor-free monolayer differentiation systems have now been developed and can differentiate hiPSCs into cardiomyocytes with a very high efficiency of 80–95% (46–49).

hiPSC-CMs have the potential to be utilized as 1) cell-based cardiac regeneration therapy; 2) as model systems for understanding cardiovascular disease; or 3) as platforms for testing drug efficacy and toxicity using human-derived cells. However, concerns have existed over the extent to which they recapitulate mature cardiomyocyte structure and function. Over the past several years, this issue has been partially addressed with their successful application to understanding basic mechanisms of several cardiovascular diseases (long QT, LEOPARD and Timothy syndromes), as well as to the screening of drugs for efficacy and toxicity (50–52). Recent publications have demonstrated the utility of hiPSC-CMs for modeling dilated (DCM) (53) and hypertrophic (HCM) cardiomyopathies (54), leading to enhanced understanding of their mechanisms at the single myocyte level, not previously possible using human cells. However, hiPSC-CMs do not mirror all aspects of adult cardiomyocytes and thus may not be appropriate models for all cardiovascular diseases. There is still much work to be accomplished to further mature hiPSC-CMs into cells that more accurately resemble adult cardiomyocytes (49,55,56).

hiPSC-CM models of cardiac disease: dilated (DCM) and hypertrophic (HCM) cardiomyopathies

Sun *et al.* recently reported the first hiPSC model of familial DCM using hiPSC-CMs from a family with a mutation (Arg173Trp) in cardiac troponin T (*TNNT2*) (53). Major findings were that hiPSC-CMs from DCM patients exhibit abnormal sarcomeric structure, reduced Ca^{2+} transients and weaker contraction ($P < 0.005$) vs. controls. The contractile dysfunction in DCM cells could be rescued by overexpression of SERCA (known to be downregulated in patients with heart failure). Treating cells chronically with the β 1-blocker metoprolol was able to partially rescue the abnormalities in sarcomeric organization.

Similarly, Lan *et al.* established the first hiPSC-CM model of HCM, using cells from a family carrying a mutation (Arg663His) in myosin heavy chain (*MYH7*) (54). Compared to controls, HCM hiPSC-CMs exhibited enlarged cell size starting 6 wks after cardiac induction, and contractile dysfunction in response to β -adrenergic agonists. Patch clamp studies revealed frequent small depolarizations resembling arrhythmia-related delayed after depolarizations (DADs), and these were associated with alterations in Ca^{2+} transients. Of interest, treatment with the Ca^{2+} channel blocker verapamil before the onset of hypertrophy (but not afterwards) normalized Ca^{2+} cycling and prevented the development of both arrhythmia and hypertrophy.

Human induced pluripotent stem cell-derived cardiomyocytes as platforms to test gene variants predictive of doxorubicin cardiotoxicity

We hypothesized that hiPSC-CMs could be utilized to test whether specific gene variants identified in human ADME or GWAS studies are responsible for altered doxorubicin cardiotoxicity, either reduced toxicity for protective variants, or enhanced toxicity for deleterious variants. To determine whether hiPSC-CMs could recapitulate doxorubicin cardiotoxicity *in vitro*, we chose an approach which we expected would have the highest yield, i.e. to focus on actual patient outcomes rather than on specific SNPs. We generated

hiPSC-CM lines from patients who developed clinical cardiotoxicity after receiving doxorubicin, and compared these to hiPSC-CMs from control patients who received doxorubicin and did not develop cardiotoxicity. Treating these two groups of cells with doxorubicin, we found increased cell death and ROS production in cells from patients who had experienced cardiotoxicity compared to cells from those who hadn't. This initial study clearly demonstrates our ability to detect patient-specific differential cardiotoxicity in hiPSC-CMs.

The next step will be to develop hiPSC-CM lines from patients with each of the individual SNPs implicated in doxorubicin cardiotoxicity (e.g. the *SLC28A3* variant) and expose these cells, along with appropriate control cells, to doxorubicin. If a difference in *in vitro* toxicity is found, this would confirm a role for that SNP in doxorubicin cardiotoxicity. The mechanism by which each variant influences toxicity can then be studied, e.g. one would expect that a drug transporter such as *SLC28A3* could affect intracellular levels of doxorubicin, which can be measured using mass spectrometry. Variants found to be in high linkage disequilibrium (LD) with each SNP can also be tested. Confirmatory studies can be performed using state-of-the-art gene editing technology, such as CRISPR or TALEN. These tools allow us to induce a specific gene variant in an isogenic control cell line, which should then replicate the effects of that variant in cells derived from patients. Finally, we can use CRISPR or TALEN to correct the gene variant in patient-derived cells, reverting the SNP back to the more common (wild type) allele. This later step should then rescue the toxicity effect.

Building upon the validation of individual SNPs, we should then be able to prepare a panel of hiPSC-CMs with each validated variant, both alone and in combination, to evaluate the interaction of multiple variants on risk and also help facilitate the development of new less toxic anthracycline analogues as well as cardioprotective agents. Although dozens of agents have been shown to be protective against doxorubicin cardiotoxicity in animal models or in non-human cardiomyocytes, most have never been translated to clinical utility. The use of human cells for screening such compounds would represent a major step forward in this arena. Ultimately, If successful, this hiPSC-CM-based platform should provide cardio-oncologists with a tool to individualize patient-specific chemotherapy protocols: for patients with high risk SNPs, protocols could reduce exposure to anthracyclines, and for patients with low risk SNPs, higher doses could be used safely, leading to enhanced cancer cure rates without an increased risk of cardiotoxicity.

Acknowledgments

This work was supported in part by a grant from the NIH (HL11708301) and from the Children's Cardiomyopathy Foundation to Dr. Bernstein; and by an American Heart Association Beginning Grant-in-Aid (14BGIA20480329) and NIH Pathway to Independence Award (K99 HL121177) to Dr. Burrige.

References

1. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. *Heart*. 2008; 94:525–33. [PubMed: 18347383]
2. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. *Cancer*. 1973; 32:302–14. [PubMed: 4353012]

3. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozenzweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. *Ann Intern Med.* 1979; 91:710–7. [PubMed: 496103]
4. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. *Cancer.* 2003; 97:2869–79. [PubMed: 12767102]
5. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. *The New England journal of medicine.* 1991; 324:808–15. [PubMed: 1997853]
6. Grenier M, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. *Semin in Oncology.* 1998; 25 (Suppl 10):72–85.
7. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. *Ann Oncol.* 2002; 13:819–29. [PubMed: 12123328]
8. van der Pal HJ, van Dalen EC, Hauptmann M, Kok WE, Caron HN, van den Bos C, et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. *Archives of internal medicine.* 2010; 170:1247–55. [PubMed: 20660845]
9. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. *J Clin Oncol.* 1997; 15:1544–52. [PubMed: 9193351]
10. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. *The New England journal of medicine.* 2000; 342:1077–84. [PubMed: 10760308]
11. Piegari E, De Angelis A, Cappetta D, Russo R, Esposito G, Costantino S, et al. Doxorubicin induces senescence and impairs function of human cardiac progenitor cells. *Basic research in cardiology.* 2013; 108:334. [PubMed: 23411815]
12. Huang X, Wu SM. Isolation and functional characterization of pluripotent stem cell-derived cardiac progenitor cells. *Curr Protoc Stem Cell Biol.* 2010; Chapter 1(Unit 1F):10. [PubMed: 20814937]
13. Shi Y, Moon M, Dawood S, McManus B, Liu PP. Mechanisms and management of doxorubicin cardiotoxicity. *Herz.* 2011; 36:296–305. [PubMed: 21656050]
14. Venditti P, Balestrieri M, De Leo T, Di Meo S. Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres. *Cardiovascular research.* 1998; 38:695–702. [PubMed: 9747437]
15. Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. *Mol Pharmacol.* 2005; 68:261–71. [PubMed: 15883202]
16. Holmberg SR, Williams AJ. Patterns of interaction between anthraquinone drugs and the calcium-release channel from cardiac sarcoplasmic reticulum. *Circulation research.* 1990; 67:272–83. [PubMed: 2165441]
17. Fajardo G, Zhao M, Berry G, Wong LJ, Mochly-Rosen D, Bernstein D. beta2-adrenergic receptors mediate cardioprotection through crosstalk with mitochondrial cell death pathways. *Journal of molecular and cellular cardiology.* 2011; 51:781–9. [PubMed: 21756913]
18. Ventura-Clapier R, Garnier A, Veksler V. Energy metabolism in heart failure. *J Physiol.* 2004; 555:1–13. [PubMed: 14660709]
19. Goormaghtigh E, Brasseur R, Huart P, Ruyschaert JM. Study of the adriamycin-cardiolipin complex structure using attenuated total reflection infrared spectroscopy. *Biochemistry.* 1987; 26:1789–94. [PubMed: 3593690]
20. Suliman HB, Carraway MS, Ali AS, Reynolds CM, Welty-Wolf KE, Piantadosi CA. The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. *The Journal of clinical investigation.* 2007; 117:3730–41. [PubMed: 18037988]
21. Ueno M, Kakinuma Y, Yuhki K, Murakoshi N, Iemitsu M, Miyauchi T, et al. Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. *J Pharmacol Sci.* 2006; 101:151–8. [PubMed: 16766856]
22. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nat Med.* 2012; 18:1639–42. [PubMed: 23104132]

23. Granger CB. Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done? *Circulation*. 2006; 114:2432–3. [PubMed: 17146002]
24. Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dube MP, Al-Saloos H, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. *J Clin Oncol*. 2012; 30:1422–8. [PubMed: 21900104]
25. Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, et al. Validation of Variants in SLC28A3 and UGT1A6 as Genetic Markers Predictive of Anthracycline-Induced Cardiotoxicity in Children. *Pediatr Blood Cancer*. 2013
26. Nagasawa K, Nagai K, Ohnishi N, Yokoyama T, Fujimoto S. Contribution of specific transport systems to anthracycline transport in tumor and normal cells. *Curr Drug Metab*. 2001; 2:355–66. [PubMed: 11766987]
27. Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM, et al. Molecular identification and characterization of novel human and mouse concentrative Na⁺-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). *The Journal of biological chemistry*. 2001; 276:2914–27. [PubMed: 11032837]
28. Zeller T, Wild P, Szymczak S, Rotival M, Schillert A, Castagne R, et al. Genetics and beyond--the transcriptome of human monocytes and disease susceptibility. *PLoS One*. 2010; 5:e10693. [PubMed: 20502693]
29. Cambien, F. Personal Communication. 2013.
30. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2010; 16:320–9. [PubMed: 20028759]
31. Iulianella A, Lohnes D. Chimeric analysis of retinoic acid receptor function during cardiac looping. *Developmental biology*. 2002; 247:62–75. [PubMed: 12074552]
32. Kashyap V, Laursen KB, Brenet F, Viale AJ, Scandura JM, Gudas LJ. RARgamma is essential for retinoic acid induced chromatin remodeling and transcriptional activation in embryonic stem cells. *J Cell Sci*. 2013; 126:999–1008. [PubMed: 23264745]
33. Delacroix L, Moutier E, Altobelli G, Legras S, Poch O, Choukrallah MA, et al. Cell-specific interaction of retinoic acid receptors with target genes in mouse embryonic fibroblasts and embryonic stem cells. *Molecular and cellular biology*. 2010; 30:231–44. [PubMed: 19884340]
34. Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. *J Clin Oncol*. 2012; 30:1415–21. [PubMed: 22124095]
35. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. *Cancer*. 2008; 112:2789–95. [PubMed: 18457324]
36. Bains OS, Karkling MJ, Lubieniecka JM, Grigliatti TA, Reid RE, Riggs KW. Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. *The Journal of pharmacology and experimental therapeutics*. 2010; 332:755–63. [PubMed: 20007405]
37. Lakhman SS, Ghosh D, Blanco JG. Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3). *Drug metabolism and disposition: the biological fate of chemicals*. 2005; 33:254–7. [PubMed: 15537833]
38. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. *Circulation*. 2005; 112:3754–62. [PubMed: 16330681]
39. Rossi D, Rasi S, Franceschetti S, Capello D, Castelli A, De Paoli L, et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. *Leukemia*. 2009; 23:1118–26. [PubMed: 19448608]
40. Lal S, Wong ZW, Sandanaraj E, Xiang X, Ang PC, Lee EJ, et al. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. *Cancer Sci*. 2008; 99:816–23. [PubMed: 18377430]

41. Armenian SH, Ding Y, Mills G, Sun C, Venkataraman K, Wong FL, et al. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. *British journal of haematology*. 2013
42. Cascales A, Pastor-Quirante F, Sanchez-Vega B, Luengo-Gil G, Corral J, Ortuno-Pacheco G, et al. Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms. *The oncologist*. 2013; 18:446–53. [PubMed: 23576480]
43. Rajic V, Aplenc R, Debeljak M, Prestor VV, Karas-Kuzelicki N, Mlinaric-Rascan I, et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. *Leukemia & lymphoma*. 2009; 50:1693–8. [PubMed: 19863340]
44. Lipshultz SE, Lipsitz SR, Kutok JL, Miller TL, Colan SD, Neuberg DS, et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. *Cancer*. 2013
45. Merkle FT, Eggan K. Modeling human disease with pluripotent stem cells: from genome association to function. *Cell Stem Cell*. 2013; 12:656–68. [PubMed: 23746975]
46. Gonzalez R, Lee JW, Schultz PG. Stepwise Chemically Induced Cardiomyocyte Specification of Human Embryonic Stem Cells. *Angew Chem Int Ed*. 2011; 50:11181–5.
47. Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. *Proc Natl Acad Sci U S A*. 2012
48. Tohyama S, Hattori F, Sano M, Hishiki T, Nagahata Y, Matsuura T, et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. *Cell Stem Cell*. 2013; 12:127–37. [PubMed: 23168164]
49. Burrige PW, Keller G, Gold JD, Wu JC. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. *Cell Stem Cell*. 2012; 10:16–28. [PubMed: 22226352]
50. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. *The New England journal of medicine*. 2010; 363:1397–409. [PubMed: 20660394]
51. Carvajal-Vergara X, Sevilla A, D'Souza SL, Ang YS, Schaniel C, Lee DF, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. *Nature*. 2010; 465:808–12. [PubMed: 20535210]
52. Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. *Nature*. 2011; 471:230–4. [PubMed: 21307850]
53. Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. *Sci Transl Med*. 2012; 4:130ra47.
54. Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. *Cell Stem Cell*. 2013; 12:101–13. [PubMed: 23290139]
55. Jung G, Bernstein D. hiPSC Modeling of Inherited Cardiomyopathies. Current treatment options in cardiovascular medicine. 2014; 16:320. [PubMed: 24838688]
56. Matsa E, Sallam K, Wu JC. Cardiac stem cell biology: glimpse of the past, present, and future. *Circulation research*. 2014; 114:21–7. [PubMed: 24385505]